AHCPR Plans Health Care Market, Managed Care Research Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

ROCKVILLE, Md-The Agency for Health Care Policy Research (AHCPR) plans to spend up to $11 million to fund two or three research centers to conduct studies of the health care market and managed care. The aim is to help policy makers understand, monitor, and anticipate how changes in the nation’s market-driven health care system affect costs, access to services, and quality of care. Interested researchers have until Sept. 2 , 1999, to submit letters of intent.

ROCKVILLE, Md—The Agency for Health Care Policy Research (AHCPR) plans to spend up to $11 million to fund two or three research centers to conduct studies of the health care market and managed care. The aim is to help policy makers understand, monitor, and anticipate how changes in the nation’s market-driven health care system affect costs, access to services, and quality of care. Interested researchers have until Sept. 2 , 1999, to submit letters of intent.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content